-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
-
Summary
-
Day One Biopharmaceuticals, Inc. quarterly/annual Cash and Cash Equivalents, Period Increase (Decrease) history and growth rate from 2019 to 2021.
- Day One Biopharmaceuticals, Inc. Cash and Cash Equivalents, Period Increase (Decrease) for the quarter ending March 31, 2022 was -$21.6M, a 119% decline year-over-year.
- Day One Biopharmaceuticals, Inc. annual Cash and Cash Equivalents, Period Increase (Decrease) for 2021 was $241M, a 1367% increase from 2020.
- Day One Biopharmaceuticals, Inc. annual Cash and Cash Equivalents, Period Increase (Decrease) for 2020 was $16.4M, a 37.9% decline from 2019.
Cash and Cash Equivalents, Period Increase (Decrease), Annual (USD)
Cash and Cash Equivalents, Period Increase (Decrease), YoY Annual Growth (%)